MedTrace Logo

Cannabinoid Receptor (CB1) Agonist Treatment in Severe Chronic Anorexia Nervosa

NCT00760695 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2013-05-10

No results posted yet for this study

Summary

A pilot study designed to reveal the effects of Marinol / dronabinol, a CB 1 agonist.

Primary end point: To estimate weight gain and EDI scores in patients receiving Marinol compared to placebo

Secondary end points: Motor and inner restlessness and hormonal changes during the treatment.

Conditions

  • Anorexia Nervosa

Interventions

DRUG

dronabinol

tablets, twice daily, for 4 weeks

DRUG

placebo

tablets, twice daily, for 4 weeks

Sponsors & Collaborators

  • Odense University Hospital

    lead OTHER

Principal Investigators

  • Andries Alin, physician · Endocrinological Department, Odense University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-10-31
Primary Completion
2011-12-31
Completion
2011-12-31

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00760695 on ClinicalTrials.gov